83.9 F
San Fernando
Thursday, Jul 7, 2022

Amgen and BioLabs LA Award Second Golden Ticket

Amgen Inc. and BioLabs LA at the Lundquist Institute announced that Karma Biotechnologies is the recipient of the annual Amgen Golden Ticket.

Karma, a Los Angeles startup focused on autoimmunity, allergy and food sensitivity treatments, will receive one year of lab space at BioLabs LA at the Lundquist Institute in Torrance, additional facility benefits and connections to Amgen executives.

Karma’s ticket is the second of three to be awarded through 2023 to support science startups in Southern California.

“We are thrilled and deeply honored that the experts at Amgen see the value and novelty of our Xavine tolerogenic vaccine platform for treating and preventing autoimmunity and allergies,” Dr. Andrew Gray, Karma’s chief executive, said in a statement. “Having access to the phenomenal resources at BioLabs LA and Amgen’s clinical development expertise will rapidly accelerate Karma’s R&D;, and help us make a difference in patients’ lives that much sooner.”

Amgen Golden Ticket winners are selected by the Thousand Oaks company’s leaders through a virtual pitch event that requires five finalists to pitch their business plans to an internal committee. The committee then evaluates the pitches on the strength and novelty of their scientific rationale, subject matter expertise and business plan viability.

“Amgen’s partnership with BioLabs LA at the Lundquist Institute is contributing to the acceleration of bioscience innovation in the Los Angeles area, aligning with our vision to progress the development of breakthrough therapies to serve patients suffering from serious illness,” Philip Tagari, Amgen’s vice president of therapeutic discovery, said in a statement.

Shares of Amgen (AMGN) closed up $2.01, or a fraction of a percent, to $232.38 on the Nasdaq Tuesday, a day when the market closed up more than 1 percent.

Antonio Pequeño IV
Antonio Pequeño IV
Antonio “Tony” Pequeño IV is a reporter covering health care, finance and law for the San Fernando Valley Business Journal. He specializes in reporting on some of the biggest names in the Valley’s biotechnology sector. In addition to his work with the Business Journal, Tony has reported with BuzzFeed News on the unsupervised use of Clearview AI, a controversial facial recognition technology. Tony, who also conducts freelance reporting, graduated from the USC’s Master of Science in Journalism program in 2021. He is in his fifth year as a journalist as of 2021.

Featured Articles

Related Articles